Literature DB >> 24106205

Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis.

Rachel T McGrath1, Maartje van den Biggelaar, Barry Byrne, Jamie M O'Sullivan, Orla Rawley, Richard O'Kennedy, Jan Voorberg, Roger J S Preston, James S O'Donnell.   

Abstract

Platelet-von Willebrand factor (VWF) is stored within α-granules and accounts for ∼20% of total VWF in platelet-rich plasma. This platelet-VWF pool is distinct from plasma-VWF and is enriched in high molecular weight multimers (HMWM). Previous studies have described significant functional discrepancies between platelet-VWF and plasma-VWF; however, the molecular basis of these differences is not well understood. We have characterized terminal glycan expression on platelet-VWF. Our findings demonstrate that platelet-VWF exists as a distinct natural glycoform. In particular, N-linked sialylation is markedly reduced (>50%) compared with plasma-VWF. Moreover, unlike plasma-VWF, platelet-VWF does not express AB blood group determinants, although precursor H antigen expression is similar to that on plasma-VWF. Because of this differential glycosylation, platelet-VWF exhibits specific resistance to ADAMTS13 proteolysis. Thus platelet activation at sites of vascular injury results in the release of high local concentrations of HMWM platelet-VWF that is more resistant to ADAMTS13, thereby facilitating platelet-plug formation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24106205     DOI: 10.1182/blood-2013-04-496851

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

2.  Investigating the clearance of VWF A-domains using site-directed PEGylation and novel N-linked glycosylation.

Authors:  Judicael Fazavana; Teresa M Brophy; Alain Chion; Niamh Cooke; Virginie Terraube; Justin Cohen; Chuenlei Parng; Debra Pittman; Orla Cunningham; Matthew Lambert; James S O'Donnell; Jamie M O'Sullivan
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

3.  Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms.

Authors:  S Albánez; K Ogiwara; A Michels; W Hopman; J Grabell; P James; D Lillicrap
Journal:  J Thromb Haemost       Date:  2016-04-27       Impact factor: 5.824

4.  Platelet-derived VWF in the stroke spotlight.

Authors:  Veronica H Flood
Journal:  Blood       Date:  2015-10-01       Impact factor: 22.113

5.  Perioperative management of patients with von Willebrand disease.

Authors:  James S O'Donnell; Michelle Lavin
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

6.  Effect of Pneumatic Tubing System Transport on Platelet Apheresis Units.

Authors:  Jevgenia Zilberman-Rudenko; Frank Z Zhao; Stephanie E Reitsma; Annachiara Mitrugno; Jiaqing Pang; Joseph J Shatzel; Beth Rick; Christina Tyrrell; Wohaib Hasan; Owen J T McCarty; Martin A Schreiber
Journal:  Cardiovasc Eng Technol       Date:  2018-05-21       Impact factor: 2.495

7.  Deciphering the Roles of N-Glycans on Collagen-Platelet Interactions.

Authors:  Christian Toonstra; Yingwei Hu; Hui Zhang
Journal:  J Proteome Res       Date:  2019-05-15       Impact factor: 4.466

8.  Endothelial Cell-Derived von Willebrand Factor Is the Major Determinant That Mediates von Willebrand Factor-Dependent Acute Ischemic Stroke by Promoting Postischemic Thrombo-Inflammation.

Authors:  Nirav Dhanesha; Prem Prakash; Prakash Doddapattar; Ira Khanna; Molly J Pollpeter; Manasa K Nayak; Janice M Staber; Anil K Chauhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-21       Impact factor: 8.311

Review 9.  Towards personalised therapy for von Willebrand disease: a future role for recombinant products.

Authors:  Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2016-03-22       Impact factor: 3.443

Review 10.  Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate.

Authors:  Jeffrey J Goldberger; Rishi Arora; David Green; Philip Greenland; Daniel C Lee; Donald M Lloyd-Jones; Michael Markl; Jason Ng; Sanjiv J Shah
Journal:  Circulation       Date:  2015-07-28       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.